By targeting differences in the metabolism of normal and diseased cells, Threshold Pharmaceuticals hopes to develop drugs that are more effective in fighting cancer. The biotechnology company focuses on discovering and developing therapeutics based on its Metabolic Targeting technology, which enhances the effectiveness of cancer treatments by identifying and targeting only cancerous cells. Its most advanced candidate is glufosfamide, which has completed late-stage trials as a treatment for pancreatic cancer and other solid tumors; Threshold is looking for a partner to continue development. The company is also investigating two other compounds, TH-302 and 2DG, as potential tumor fighters.